N
NeoGenomics NEO
$16.02
−3.14%
Nov 13
1W
1M
3M
6M
1Y
3Y
5Y
Activities
Key indicators
Sales
+11%
$788M over 12 months
Net margin
−4%
Low
High
Volatility
54%
Calm
Choppy
Bars: against the 19 close companies.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
Earnings release
The day the company publishes its quarterly accounts: revenue, profit, and often its outlook. The price sometimes moves sharply that day, in either direction. Over the long term, what matters is the trend of profits from one quarter to the next, not the reaction of the day.
Posts
No posts about NEO yet.
About NeoGenomics, Inc. Common Stock
NeoGenomics runs cancer-testing laboratories in the US and England. It earns money by charging hospitals, doctors and insurers for genetic and tissue tests that guide cancer treatment, and by selling testing services to drug companies. Next-generation sequencing, a method that reads many genes at once, is its fastest-growing business.